Mesenchymal stem cell therapies - Stempeutics

Drug Profile

Mesenchymal stem cell therapies - Stempeutics

Alternative Names: ex-vivo cultured adult human mesenchymal stem cells - Stempeutics; ex vivo cultured adult allogenic mesenchymal stem cells - Stempeutics; ex-vivo cultured adult bone marrow derived allogeneic mesenchymal stem cells - Stempeutics; Stempeucel; stempeucel AMI™; stempeucel CLI™; stempeucel COPD™; stempeucel CS™; stempeucel DCM™; stempeucel DM™; stempeucel LC™; stempeucel OA™

Latest Information Update: 20 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Stempeutics
  • Class Antineoplastics; Stem cell therapies
  • Mechanism of Action Osteogenesis stimulants; Tissue replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Thromboangiitis obliterans
  • New Molecular Entity No
  • Available For Licensing Yes - Osteoarthritis; Peripheral ischaemia

Highest Development Phases

  • Registered Peripheral ischaemia
  • Phase II Osteoarthritis
  • No development reported Chronic obstructive pulmonary disease; Dilated cardiomyopathy; Liver cirrhosis; Myocardial infarction; Stroke; Type 2 diabetes mellitus

Most Recent Events

  • 05 Apr 2017 Stempeutics withdrew a phase II trial prior to enrolment as DCGI directed to conduct PMS study for Peripheral ischemia (In adults) in India (NCT03056742)
  • 21 Feb 2017 Stempeutics plans a phase II trial for Peripheral ischemia in India (NCT03056742)
  • 30 May 2016 Registered for Peripheral ischaemia in India (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top